{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-24-000026","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.072847+00:00","generated_at":"2026-06-02T09:07:16.761758+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Supernus Q1: Qelbree sales +75% to $45.1M; SPN-830 gets FDA CRL; FY guidance reiterated","bullets":["Total revenue of $143.6M; Qelbree net sales surged 75% YoY to $45.1M (IQVIA Rx +31%).","Operating loss of $(3.2)M; adjusted operating earnings (non-GAAP) of $22.3M.","Full-year 2024 guidance reaffirmed: total revenue $580M-$620M, adjusted op. earnings $80M-$110M.","FDA issued Complete Response Letter for SPN-830 (apomorphine infusion) in Parkinson's; resubmission after May 2024 FDA meeting.","SPN-820 Phase IIb >50% enrolled; topline data H1 2025. SPN-817 interim data call May 23; SPN-443 Phase I planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-24-000026","json":"https://secwatch.observer/filing/0001356576-24-000026.json","markdown":"https://secwatch.observer/filing/0001356576-24-000026.md","text":"https://secwatch.observer/filing/0001356576-24-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000026/0001356576-24-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000026/supn-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:07:16.761758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4023c29113bb3276ea64ebc9083d2b3e7b7e2548","claim":"SUPERNUS PHARMACEUTICALS, INC. updated its the first quarter of 2024 guidance (reaffirmed).","evidence_excerpt":"On May 8, 2024, Supernus Pharmaceuticals, Inc. (\"Supernus\" or the \"Company\") issued a press release regarding its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000026/0001356576-24-000026-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2024"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}